Related references
Note: Only part of the references are listed.Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
P. Vuylsteke et al.
ANNALS OF ONCOLOGY (2016)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Neil A. O'Brien et al.
CLINICAL CANCER RESEARCH (2014)
Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors
Jordi Rodon et al.
INVESTIGATIONAL NEW DRUGS (2014)
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia
A. Lonetti et al.
LEUKEMIA (2014)
A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity
Nicholas M. Levinson et al.
NATURE CHEMICAL BIOLOGY (2014)
Inhibition of Phosphatidylinositol 3-Kinase/AKT Signaling by NVP-BKM120 Promotes ABT-737-Induced Toxicity in a Caspase-Dependent Manner through Mitochondrial Dysfunction and DNA Damage Response in Established and Primary Cultured Glioblastoma Cells
Esther P. Jane et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Challenges in the clinical development of PI3K inhibitors
Cristian Massacesi et al.
INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE (2013)
PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas
Katherine Walsh et al.
CLINICAL CANCER RESEARCH (2013)
The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro
Lilian Amrein et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Structural basis of tubulin tyrosination by tubulin tyrosine ligase
Andrea E. Prota et al.
JOURNAL OF CELL BIOLOGY (2013)
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
Martha M. Kirstein et al.
LIVER INTERNATIONAL (2013)
Metrics other than potency reveal systematic variation in responses to cancer drugs
Mohammad Fallahi-Sichani et al.
NATURE CHEMICAL BIOLOGY (2013)
End-binding proteins sensitize microtubules to the action of microtubule-targeting agents
Renu Mohan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Molecular Mechanism of Action of Microtubule-Stabilizing Anticancer Agents
Andrea E. Prota et al.
SCIENCE (2013)
Towards automated crystallographic structure refinement with phenix.refine
Pavel V. Afonine et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2012)
Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines
Annett Mueller et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo
Hui Ren et al.
CANCER LETTERS (2012)
Antitumor Activity of NVP-BKM120-A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells
Dimpy Koul et al.
CLINICAL CANCER RESEARCH (2012)
A Computational Study of the Oligosaccharide Binding Sites in the Lectin-Like Domain of Tumor Necrosis Factor and the TNF-derived TIP Peptide
Alexander Dulebo et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations
Saskia M. Brachmann et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Multi-Level Targeting of the Phosphatidylinositol-3-Kinase Pathway in Non-Small Cell Lung Cancer Cells
Christopher R. Zito et al.
PLOS ONE (2012)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
Cesar G. Sanchez et al.
BREAST CANCER RESEARCH (2011)
MolProbity: all-atom structure validation for macromolecular crystallography
Vincent B. Chen et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
In Vitro Reconstitution of the Functional Interplay between MCAK and EB3 at Microtubule Plus Ends
Susana Montenegro Gouveia et al.
CURRENT BIOLOGY (2010)
A Medicinal Chemist's Guide to Molecular Interactions
Caterina Bissantz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Tubulin: A Target for Antineoplastic Drugs into the Cancer Cells but also in the Peripheral Nervous System
Annalisa Canta et al.
CURRENT MEDICINAL CHEMISTRY (2009)
PI3Kγ Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P3 Pools in Mast Cells
Thomas Bohnacker et al.
SCIENCE SIGNALING (2009)
Optimization of taxane binding to microtubules: Binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel
Ruth Matesanz et al.
CHEMISTRY & BIOLOGY (2008)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
CLASP1 and CLASP2 bind to EB1 and regulate microtubule plus-end dynamics at the cell cortex
Y Mimori-Kiyosue et al.
JOURNAL OF CELL BIOLOGY (2005)
Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain
RBG Ravelli et al.
NATURE (2004)
Cation-π interactions in ligand recognition and catalysis
N Zacharias et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2002)
Refined structure of αβ-tubulin at 3.5 A resolution
J Löwe et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Share Paper
